Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.85 |
| ▸ | PPARG | P37231 | 7/20 | 0.85 |
| ▸ | PPARD | Q03181 | 7/20 | 0.85 |
| ▸ | PPARA | Q07869 | 7/20 | 0.85 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.85 |
| ▸ | TSHR | P16473 | 4/20 | 0.85 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.85 |
| ▸ | FABP4 | P15090 | 3/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.85 |
| ▸ | TLR2 | O60603 | 2/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.85 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.85 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | ESR1 | P03372 | 1/20 | 0.85 |
| ▸ | PDE4A | P27815 | 1/20 | 0.85 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanoic Acid SCHEMBL873761 | 1.00 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL6066257 | 1.00 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 | |
| Octanoic Acid SCHEMBL1275148 | 1.00 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL4204219 | 1.00 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 | |
| Sebacic Acid SCHEMBL11510695 | 1.00 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL18076283 | 1.00 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL11077205 | 1.00 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL43379 | 1.00 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL17812647 | 1.00 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL8161929 | 1.00 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115804753-A | Agomelatine self-microemulsion composition, capsule and application thereof | 湖南慧泽生物医药科技有限公司 | 2023-03-17 | — | — | CN | claimed |
| US-20080249147-A1 | Emulsion-Stabilized Preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-09 | — | — | US | claimed |
| EP-1728504-A1 | EMULSION STABILIZER | Takeda Pharmaceutical Company Limited (JP) | 2006-12-06 | — | — | EP | claimed |
| CN-117771249-A | Lapattinib self-microemulsion composition and preparation method thereof | 湖南慧泽生物医药科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115968302-A | Compositions and methods for treating gene therapy patients | 宾夕法尼亚州大学信托人 | 2023-04-14 | — | — | CN | disclosed |
| CN-115616013-A | Method for representing in-situ structure of drug in drug inclusion based on small-angle neutron scattering | 松山湖材料实验室 | 2023-01-17 | — | — | CN | disclosed |
| CN-112618488-B | Self-microemulsion formulations of axitinib | 湖南慧泽生物医药科技有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-112516315-B | Self-microemulsion composition of tyrosine kinase inhibitor | 湖南慧泽生物医药科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-112618488-A | Self-microemulsion formulations of axitinib | 湖南慧泽生物医药科技有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112516315-A | Self-microemulsion composition of tyrosine kinase inhibitor | 湖南慧泽生物医药科技有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-1728505-B1 | PREPARATION WITH ELEVATED CONTENT | TAKEDA PHARMACEUTICAL (JP) | 2014-06-04 | — | — | EP | disclosed |
| EP-1728504-B1 | EMULSION STABILIZER | TAKEDA PHARMACEUTICAL (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20080249147-A1 | Emulsion-Stabilized Preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080234343-A1 | Preparation with Elevated Content | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1728505-A1 | PREPARATION WITH ELEVATED CONTENT | Takeda Pharmaceutical Company Limited (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1728504-A1 | EMULSION STABILIZER | Takeda Pharmaceutical Company Limited (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249147-A1 | Emulsion-Stabilized Preparation | LIPA, MGLL, SI | GPR84 494/4885PPARG 125/4885PPARD 171/4885 |
| US-20080234343-A1 | Preparation with Elevated Content | SI, CEL, ABCB11 | GPR84 2334/4885PPARG 814/4885PPARD 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.